Show simple item record

dc.contributor.authorVan Akkooi, A. C. J.en
dc.contributor.authorHauschild, A.en
dc.contributor.authorLong, G. V.en
dc.contributor.authorMandalà, M.en
dc.contributor.authorKicinski, M.en
dc.contributor.authorGovaerts, A. S.en
dc.contributor.authorKlauck, I.en
dc.contributor.authorOuali, M.en
dc.contributor.authorLorigan, Paul Cen
dc.contributor.authorEggermont, A. M.en
dc.date.accessioned2023-10-25T08:48:39Z
dc.date.available2023-10-25T08:48:39Z
dc.date.issued2023en
dc.identifier.citationVan Akkooi ACJ, Hauschild A, Long GV, Mandalà M, Kicinski M, Govaerts AS, et al. Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005520.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.TPS9601en
dc.identifier.urihttp://hdl.handle.net/10541/626667
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS9601en
dc.titlePhase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study designen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMelanoma Institute Australia, Wollstonecraft, Australiaen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record